Overview

A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer

Status:
Unknown status

Trial end date:
2010-05-01

Target enrollment:

Participant gender:

Summary

Docetaxol plus capecitabine regimen is the standard treatment for the anthracycline-pretreated patients with advanced breast cancer. Cisplatin is an important drug for advanced breast cancer and potential effective drug for triple negative breast cancer.The study primary objective:Assess ORR,TTP,TTF and 2 year PFS rate between docetaxol+capecitabine and docetaxol+cisplatin. The second objective:Assess the safety and QOL.

Phase:

Phase 2

Details

Lead Sponsor:

Academy Military Medical Science, China

Collaborator:

Chinese Academy of Medical Sciences

Treatments:

Capecitabine
Cisplatin
Docetaxel